Ignite Creation Date:
2025-12-24 @ 10:14 PM
Ignite Modification Date:
2025-12-25 @ 7:48 PM
Study NCT ID:
NCT04221035
Status:
RECRUITING
Last Update Posted:
2025-06-26
First Post:
2020-01-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D014750', 'term': 'Vincristine'}, {'id': 'D016190', 'term': 'Carboplatin'}, {'id': 'D005047', 'term': 'Etoposide'}, {'id': 'D014751', 'term': 'Vindesine'}, {'id': 'D003606', 'term': 'Dacarbazine'}, {'id': 'D007069', 'term': 'Ifosfamide'}, {'id': 'D004317', 'term': 'Doxorubicin'}, {'id': 'D002066', 'term': 'Busulfan'}, {'id': 'D008558', 'term': 'Melphalan'}, {'id': 'D013852', 'term': 'Thiotepa'}, {'id': 'D011878', 'term': 'Radiotherapy'}, {'id': 'C112746', 'term': 'dinutuximab'}, {'id': 'D002945', 'term': 'Cisplatin'}, {'id': 'D000077204', 'term': 'Temozolomide'}, {'id': 'D000077146', 'term': 'Irinotecan'}, {'id': 'D003520', 'term': 'Cyclophosphamide'}], 'ancestors': [{'id': 'D014748', 'term': 'Vinca Alkaloids'}, {'id': 'D046948', 'term': 'Secologanin Tryptamine Alkaloids'}, {'id': 'D026121', 'term': 'Indole Alkaloids'}, {'id': 'D000470', 'term': 'Alkaloids'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D007211', 'term': 'Indoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D054836', 'term': 'Indolizidines'}, {'id': 'D007212', 'term': 'Indolizines'}, {'id': 'D056831', 'term': 'Coordination Complexes'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011034', 'term': 'Podophyllotoxin'}, {'id': 'D013764', 'term': 'Tetrahydronaphthalenes'}, {'id': 'D009281', 'term': 'Naphthalenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D005960', 'term': 'Glucosides'}, {'id': 'D006027', 'term': 'Glycosides'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D014226', 'term': 'Triazenes'}, {'id': 'D007093', 'term': 'Imidazoles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D010752', 'term': 'Phosphoramide Mustards'}, {'id': 'D009588', 'term': 'Nitrogen Mustard Compounds'}, {'id': 'D009150', 'term': 'Mustard Compounds'}, {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'}, {'id': 'D063088', 'term': 'Phosphoramides'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}, {'id': 'D010078', 'term': 'Oxazines'}, {'id': 'D003630', 'term': 'Daunorubicin'}, {'id': 'D018943', 'term': 'Anthracyclines'}, {'id': 'D009279', 'term': 'Naphthacenes'}, {'id': 'D000617', 'term': 'Aminoglycosides'}, {'id': 'D002072', 'term': 'Butylene Glycols'}, {'id': 'D006018', 'term': 'Glycols'}, {'id': 'D000438', 'term': 'Alcohols'}, {'id': 'D008698', 'term': 'Mesylates'}, {'id': 'D000476', 'term': 'Alkanesulfonates'}, {'id': 'D017738', 'term': 'Alkanesulfonic Acids'}, {'id': 'D000473', 'term': 'Alkanes'}, {'id': 'D006839', 'term': 'Hydrocarbons, Acyclic'}, {'id': 'D013451', 'term': 'Sulfonic Acids'}, {'id': 'D013456', 'term': 'Sulfur Acids'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D010649', 'term': 'Phenylalanine'}, {'id': 'D024322', 'term': 'Amino Acids, Aromatic'}, {'id': 'D000598', 'term': 'Amino Acids, Cyclic'}, {'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D013721', 'term': 'Triethylenephosphoramide'}, {'id': 'D001388', 'term': 'Aziridines'}, {'id': 'D001389', 'term': 'Azirines'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D017606', 'term': 'Chlorine Compounds'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D017672', 'term': 'Nitrogen Compounds'}, {'id': 'D017671', 'term': 'Platinum Compounds'}, {'id': 'D002166', 'term': 'Camptothecin'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 800}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2019-11-05', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-06', 'completionDateStruct': {'date': '2032-11', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-06-25', 'studyFirstSubmitDate': '2020-01-06', 'studyFirstSubmitQcDate': '2020-01-06', 'lastUpdatePostDateStruct': {'date': '2025-06-26', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-01-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-11', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Event free survival (EFS)', 'timeFrame': 'Assessed at each end of randomization sequences up to one year', 'description': 'Event free survival'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['High-Risk Neuroblastoma', 'Patient With Insufficient Response Chemoimmunotherapy']}, 'descriptionModule': {'briefSummary': 'This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.', 'detailedDescription': 'This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.\n\nThe first randomization (R-I) will compare the efficacy of two induction chemotherapies (RAPID COJEC and GPOH regimens) in a phase III setting. The primary endpoint will be the 3-year EFS from date of randomization . The R-I randomization will be stratified on age, stage, MYCN status and countries.\n\nThe second randomization (R-HDC) will compare the efficacy of single HDC with Bu-Mel versus tandem HDC with Thiotepa followed by Bu-Mel. The primary endpoint is 3-year EFS calculated from the date of the R-HDC randomization. The R-HDC randomization will be stratified on the age, stage, MYCN status, induction chemotherapy regimen, response to induction phase and countries.\n\nThe impact of local treatment in this phase III setting will be assessed, according to the presence or not of a macroscopic residual disease after surgery and HDC.\n\nIn case of macroscopic residual disease, 21.6 Gy radiotherapy to the preoperative tumor bed will be randomized (R-RTx) versus the same treatment plus a sequential boost of additional 14.4 Gy to the residual tumor. The primary endpoint of R-RTx is 3-year EFS from the date of the R-RTx randomization. The R-RTx randomization will be stratified on age, stage, MYCN status, induction chemotherapy regimen, HDC regimen and countries.\n\nIn case of no macroscopic residual disease, 21.6 Gy radiotherapy will be delivered to the preoperative tumor bed.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '21 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nEnrollment in HR-NBL2 will be performed:\n\n* at diagnosis before the beginning of chemotherapy or\n* up to 21 days after one course of Carboplatin-Etoposide for patients with localized neuroblastoma or infants with metastatic neuroblastoma with MYCN amplification or patients with metastatic neuroblastoma treated in emergency or\n* up to 21 days after one course of the current protocol for R-I randomisation (RAPID COJEC/GPOH) low/intermediate risk neuroblastoma in Germany/Netherlands for patients with localized neuroblastoma or infants with metastatic neuroblastoma with MYCN amplification\n\nHR-NBL2 eligibility criteria:\n\n1. Established diagnosis of neuroblastoma according to the SIOPEN- modified International Neuroblastoma Risk Group (INRG) criteria, High-risk neuroblastoma defined as:\n\n * Stage M neuroblastoma above 365 days of age at diagnosis (no upper age limit) and Ms neuroblastoma 12-18 months old, any MYCN status or\n * L2, M or Ms neuroblastoma any age with MYCN amplification, or focal high level MYC or MYCL amplification.\n\n In Germany, patients aged less than 18 months with stage M and without MYCN amplification will not be enrolled in HR-NBL2 trial.\n2. No previous chemotherapy or up to 21 days after one cycle of Carboplatin-Etoposide chemotherapy for patients with localized neuroblastoma or infants with metastatic neuroblastoma with MYCN amplification or patients with metastatic neuroblastoma treated in emergency or up to 21 days after one course of the current protocol for low/intermediate risk neuroblastoma in Germany/Netherlands for patients with localized neuroblastoma or infants with metastatic neuroblastoma with MYCN amplification\n3. Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to initiation of treatment. Sexually active patients must agree to use acceptable and appropriate contraception while on HR-NBL2 study and for one year after stopping the study. Acceptable contraception is defined in CTFG Guidelines "Recommendations related to contraception and pregnancy testing in clinical trials" (Appendix 11). Female patients who are lactating must agree to stop breast-feeding.\n4. Written informed consent to enter the HR-NBL2 protocol from patient or parents/legal representative, patient, and age-appropriate assent.\n5. Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.\n6. Patients should be able and willing to comply with study visits and procedures as per protocol\n\nR-I eligibility criteria:\n\n\\- Written informed consent to enter the R-I randomisation from patient or parents/legal representative, patient, and age- appropriate assent.\n\nIn case of parents\'/patient\'s refusal to R-I, or Organ toxicity exclusion criteria at diagnosis, patients can still be enrolled in HR- NBL2 trial with parents\'/patient\'s consent before or within 3 weeks from the beginning of chemotherapy\n\nR-HDC randomisation (Single HDC Bu-Mel/ Tandem HDC Thiotepa+Bu-Mel) Etoposide or one course of the current protocol for low/intermediate risk neuroblastoma in Germany/Netherlands). Patients will be treated with the standard induction regimen per country (Rapid COJEC or GPOH) and will be potentially eligible for subsequent randomisations.\n\nRandomisation for HDC strategy will be performed at the end of induction after the disease evaluation and after surgery of the primary tumour for those patients who will receive surgery before HDC.\n\nR-HDC eligibility criteria:\n\n1. \\- Stage M neuroblastoma above 365 days of age at diagnosis, any MYCN status, EXCEPT patients with stage M or Ms 12-18 months old with numerical chromosomal alterations only, and in complete metastatic response at the end of induction: in this case, patients will have surgery and no further treatment.\n\n OR\n\n \\- L2, M or Ms neuroblastoma, any age, with MYCN amplification, or focal high level MYC or MYCL amplification\n2. Age \\< 21 years at the time of randomization\n3. Complete response (CR) or partial response (PR) at metastatic sites:\n\n * Bone disease: mIBG uptake completely resolved or SIOPEN score ≤ 3 and at least 50% reduction in mIBG score (or ≤ 3 bone lesions and at least 50% reduction in number of FDG- PET-avid bone lesions for mIBG-nonavid tumours).\n * Bone marrow disease: CR and/or minimal disease (MD) according to International Neuroblastoma Response Criteria\n * Other metastatic sites: CR. (after induction chemotherapy +/- surgery), except for distant lymph nodes for which PR is accepted with a possible secondary surgery\n4. Acceptable organ function and performance status:\n\n * Performance status ≥ 50%.\n * Hematological status: ANC\\>0.5x109/L, platelets \\> 20x 109/L\n * Cardiac function: (\\< grade 2)\n * Normal chest X-Ray and oxygen saturation.\n * Absence of any toxicity ≥ grade 3. 4) Sufficient collected stem cells available; a total harvest of at least 6 x 106/kg CD34+ cells, to be stored in at least 4 separate bags to administer at least 3 x 106/kg CD34+ cells per rescue.\n5. Written informed consent, including agreement of patient or parents/legal guardian for minors, to enter the R-HDC randomisation.\n6. Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.\n7. Patients should be able and willing to comply with study visits and procedures as per protocol.\n\nIn case of parents\'/patient\'s refusal, or insufficient stem cells, collection for tandem HDC but with a minimum of 3 x 106 CD34+ cells/kg body weight, or in case of patients older than 21 years, or organ toxicity, HDC will consist on the standard HD Bu-Mel and patients will be eligible for the subsequent randomisation.\n\nR-RTx randomisation (Local Radiotherapy) Chemoimmunotherapy arm\n\nR-RTx eligibility criteria:\n\nAn evaluation of the local disease will be performed after HDC/ASCR and surgery:\n\n* In case of no local macroscopic disease, all patients will receive 21,6-Gy radiotherapy to the pre-operative tumour bed\n* In case of local macroscopic residual disease, patients will be eligible to R-RTx if the following criteria are met:\n\n 1. No evidence of disease progression after HDC/ASCR.\n 2. Interval between the last ASCR and radiotherapy start between 60 and 90 days.\n 3. Performance status greater or equal 50%.\n 4. Hematological status: ANC \\>0.5x109/L, platelets \\> 20x109/L.\n 5. Written informed consent, including agreement of patient or parents/legal guardian for minors, to enter the R-RTx randomisation.\n 6. Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.\n 7. Patients should be able and willing to comply with study visits and procedures as per protocol.\n\nIn case of parents\'/patient\'s refusal of the randomisation, the patient will receive 21.6 Gy radiotherapy to the pre-operative tumour bed.\n\nChemoimmunotherapy arm eligibility criteria:\n\n1. Insufficient metastatic response at the end of induction chemotherapy, defined as:\n\n * SIOPEN score \\> 3 or less than 50% reduction in mIBG score (or \\> 3 bone lesions or less 50% reduction in number of FDG-PET-avid bone lesions for mIBG-non avid tumours) OR\n * Bone marrow disease: SD according to International Neuroblastoma Response Criteria OR\n * Other metastatic sites: PR or SD. For distant lymph nodes: PR and not resectable or SD.\n2. Performance status ≥ 50%.\n3. Hematological status: ANC\\>0.75x109/L without G-CSF for at least 48 hours (or ANC ≥ 0.50 x 109 /L in case of bone marrow involvement), platelets \\> 50x 109/L and rising, without platelets transfusion for 72 hours.\n4. AST or ALT ≤7.5 ULN and total bilirubin ≤1.5 ULN. In patients with liver metastases, total bilirubin ≤2.5 ULN is allowed.\n5. No active infection;\n6. No grade \\>2 gastrointestinal toxicity.\n7. No grade ≥ 3 toxicity related to previous treatment.\n8. Oxygen saturation \\> 94%\n\nNon-inclusion criteria for HR-NBL2:\n\n1. Any negative answer concerning the HR-NLB2 inclusion criteria\n2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving his consent.\n3. Participating in another clinical study with an IMP while on study treatment.\n4. Chronic inflammatory bowel disease and/or bowel obstruction.\n5. Pregnant or breastfeeding women.\n6. Known hypersensitivity to the active substance or to any of the excipients of the study drugs\n7. Concomitant self-medication medicine that in the investigator opinion could interact with study treatments, including herbal medicine (e.g. St John\'s Wort (Hypericum Perforatum).\n\nNon-inclusion criteria specific to the R-I randomisation (RAPID COJEC/GPOH):\n\n1. Urinary tract obstruction ≥ grade 3\n2. Heart failure or myocarditis ≥ grade 2, any arrhythmia or myocardial infection\n3. Peripheral motor or sensory neuropathy ≥ grade 3\n4. Demyelinating form of Charcot-Marie-Tooth syndrome\n5. Hearing impairment ≥ grade 2\n6. Concurrent prophylactic use of phenytoin\n7. Cardiorespiratory disease that contraindicates hyperhydration\n\nNon-inclusion criteria common to all randomisations (R-I, R-HDC, and R-RTx):\n\n1. Any negative answer concerning the inclusion criteria of R-I or R- HDC or R-RTx will render the patient ineligible for the corresponding therapy phase randomisation. However, these patients may remain on study and be considered to receive standard treatment of the respective therapy phase, and may be potentially eligible for subsequent randomisations.\n2. Liver function: Alanine aminotransferase (ALT) \\> 3.0 x ULN and blood bilirubin \\> 1.5 x ULN (toxicity ≥ grade 2). In case of toxicity ≥ grade 2, call national principal investigator study coordinator to discuss the feasibility.\n3. Renal function: Creatinine clearance and/or GFR \\< 60 ml/min/1.73m² (toxicity ≥ grade 2). If GFR \\< 60ml/min/1.73m², call national principal investigator study coordinator to discuss about the treatment.\n4. Dyspnea at rest and/or pulse oximetry \\<95% in air (only for R-HDC, and R-RTx)\n5. Any uncontrolled intercurrent illness or infection that in the investigator opinion would impair study participation.\n6. Concomitant use with yellow fever vaccine and with live virus or bacterial vaccines.\n7. Patient allergic to peanut or soya.\n\nNon-inclusion criteria to R-HDC:\n\n\\- Any negative answer concerning the R-HDC inclusion criteria\n\nNon-inclusion criteria to chemoimmunotherapy arm:\n\n\\- Any negative answer concerning the inclusion criteria of chemoimmunotherapy arm.'}, 'identificationModule': {'nctId': 'NCT04221035', 'acronym': 'HR-NBL2', 'briefTitle': 'High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)', 'organization': {'class': 'OTHER', 'fullName': 'Gustave Roussy, Cancer Campus, Grand Paris'}, 'officialTitle': 'High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)', 'orgStudyIdInfo': {'id': '2019-001068-31'}, 'secondaryIdInfos': [{'id': '2019/2894', 'type': 'OTHER', 'domain': 'CSET number (Gustave Roussy ID)'}, {'id': '2024-514917-36-00', 'type': 'CTIS'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'phase induction-R-I', 'description': 'R-I: induction regimens RAPID COJEC vs GPOH Assuming a baseline 3-year EFS of 40%, with a sample size of 686 patients (343 in each arm) and a two-sided alpha=5% this trial will have 90% power to demonstrate an improvement of 12% in 3-year EFS, within a recruitment period of 3 years and a minimum follow up of 1.5 years.\n\nPatients with insufficient metastatic response at the end of induction chemotherapy, defined as SIOPEN score \\> 3 or less than 50% reduction in mIBG score (or \\> 3 bone lesions or less 50% reduction in number of FDG-PET-avid bone lesions for mIBG-non avid tumours), have a poorer prognosis.\n\nChemoimmunotherapy arm Metastatic response rate after 4 courses of irinotecan-temozolomide (TEMIRI) combined with dinutuximab beta (DB) in patients with insufficient metastatic response at the end of induction chemotherapy (TEMIRI/DB).', 'interventionNames': ['Drug: Vincristine', 'Drug: Carboplatin', 'Drug: Etoposide', 'Drug: Vindesine', 'Drug: Dacarbazine', 'Drug: Ifosfamide', 'Drug: Doxorubicin', 'Drug: Dinutuximab Beta', 'Drug: Cisplatin', 'Drug: Temozolomide 100 MG', 'Drug: Irinotecan', 'Drug: Cyclophosphamid']}, {'type': 'EXPERIMENTAL', 'label': 'Phase high dose chemotherapy consolidation', 'description': 'R-HDC: consolidation regimen Bu-Mel vs Thiotepa + Bu-Mel The 3-year EFS in the Bu-Mel arm (with immunotherapy) is estimated to be 55%. This study aims to show an improvement of 12% for the Thiotepa + Bu-Mel arm (3-year EFS of 67%). With a recruitment of 448 patients (224 in each arm) over a period of 3 years and a minimum follow-up of 2 years, the power to show a 12% difference is 80% (two-sided logrank test and α=5%).', 'interventionNames': ['Drug: Busulfan', 'Drug: Melphalan', 'Drug: Thiotepa']}, {'type': 'EXPERIMENTAL', 'label': 'Phase of radiotherapy', 'description': 'R-RTx: 21.6 Gy radiotherapy vs 21.6 Gy + 14.4 Gy boost in patients with macroscopic residual disease', 'interventionNames': ['Radiation: Radiotherapy', 'Drug: Dinutuximab Beta']}], 'interventions': [{'name': 'Vincristine', 'type': 'DRUG', 'otherNames': ['L01CA02'], 'description': '1.5 mg/m2 (max dose 2 mg)', 'armGroupLabels': ['phase induction-R-I']}, {'name': 'Carboplatin', 'type': 'DRUG', 'otherNames': ['LO1XA02'], 'description': '750 mg/m2', 'armGroupLabels': ['phase induction-R-I']}, {'name': 'Etoposide', 'type': 'DRUG', 'otherNames': ['L01CB01'], 'description': '175 mg/m2', 'armGroupLabels': ['phase induction-R-I']}, {'name': 'Vindesine', 'type': 'DRUG', 'otherNames': ['L01CA03'], 'description': '3 mg/m2/day (max dose 6 mg)', 'armGroupLabels': ['phase induction-R-I']}, {'name': 'Dacarbazine', 'type': 'DRUG', 'otherNames': ['L01AX04'], 'description': '200 mg/m2/day', 'armGroupLabels': ['phase induction-R-I']}, {'name': 'Ifosfamide', 'type': 'DRUG', 'description': '1500 mg/m2/day', 'armGroupLabels': ['phase induction-R-I']}, {'name': 'Doxorubicin', 'type': 'DRUG', 'otherNames': ['L01DB01'], 'description': '30 mg/m2/dose', 'armGroupLabels': ['phase induction-R-I']}, {'name': 'Busulfan', 'type': 'DRUG', 'otherNames': ['L01AB01'], 'description': '\\< 9kg: 1.0 mg/kg/dose 9 kg to \\< 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose \\>23 kg to 34 kg: 0.95 mg/kg/dose \\>34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses', 'armGroupLabels': ['Phase high dose chemotherapy consolidation']}, {'name': 'Melphalan', 'type': 'DRUG', 'otherNames': ['L01AA03'], 'description': "140 mg/m2/dose IV short infusion (15'), at least 24 h after the last busulfan dose", 'armGroupLabels': ['Phase high dose chemotherapy consolidation']}, {'name': 'Thiotepa', 'type': 'DRUG', 'otherNames': ['L01AC01'], 'description': '300 mg/m2/day over 2 hours', 'armGroupLabels': ['Phase high dose chemotherapy consolidation']}, {'name': 'Radiotherapy', 'type': 'RADIATION', 'description': '21.6 Gy 21.6 Gy + boost de 14.4 Gy', 'armGroupLabels': ['Phase of radiotherapy']}, {'name': 'Dinutuximab Beta', 'type': 'DRUG', 'otherNames': ['L01XC16'], 'description': 'Patients \\>12 kg are dosed based on the BSA: 10 mg/m\\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day', 'armGroupLabels': ['Phase of radiotherapy', 'phase induction-R-I']}, {'name': 'Cisplatin', 'type': 'DRUG', 'otherNames': ['L01XA01'], 'description': '80 mg/m2/24h', 'armGroupLabels': ['phase induction-R-I']}, {'name': 'Temozolomide 100 MG', 'type': 'DRUG', 'description': '100 mg/m²/Day', 'armGroupLabels': ['phase induction-R-I']}, {'name': 'Irinotecan', 'type': 'DRUG', 'description': '50 mg/m²/jour de J0 à J4', 'armGroupLabels': ['phase induction-R-I']}, {'name': 'Cyclophosphamid', 'type': 'DRUG', 'description': 'Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.', 'armGroupLabels': ['phase induction-R-I']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'NSW, 2031', 'city': 'Sydney', 'state': 'Randwick', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Toby Nicholas Trahair, Phd, MD', 'role': 'CONTACT', 'email': 'Toby.Trahair@health.nsw.gov.au', 'phone': '61 2 9382 2970'}], 'facility': 'Sydney children Hospital', 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'zip': 'VIC 3168', 'city': 'Clayton', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Peter Downie, MD', 'role': 'CONTACT', 'email': 'Peter.Downie@monashhealth.org'}], 'facility': "Children's Cancer Centre, Monash Children's Hospital", 'geoPoint': {'lat': -37.91667, 'lon': 145.11667}}, {'zip': 'WA, 6009', 'city': 'Nedlands', 'status': 'SUSPENDED', 'country': 'Australia', 'facility': "Oncology/Haematology Department, Perth Children's Hospital", 'geoPoint': {'lat': -31.98184, 'lon': 115.8073}}, {'zip': 'NSW, 2305', 'city': 'New Lambton Heights', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Janis chamberlin, MD', 'role': 'CONTACT', 'email': 'Janis.Chamberlain@health.nsw.gov.au', 'phone': '61 2 4921 3080'}], 'facility': "Children's Cancer & Haematology Services, John Hunter Children's Hospital", 'geoPoint': {'lat': -32.92466, 'lon': 151.69364}}, {'zip': 'NSW, 2031', 'city': 'Sydney', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'Australia', 'facility': "Australian and New Zealand Children's Hematology/oncology Group", 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'zip': 'NSW, 2031', 'city': 'Sydney', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'toby trahair, MD', 'role': 'CONTACT', 'email': 'Toby.Trahair@health.nsw.gov.au', 'phone': '61 2 9382 2970'}], 'facility': 'sydney children Hospital', 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'zip': 'NSW, 2145,', 'city': 'Westmead', 'status': 'SUSPENDED', 'country': 'Australia', 'facility': "Cancer Centre for Children, The Children's Hospital", 'geoPoint': {'lat': -33.80383, 'lon': 150.98768}}, {'city': 'Graz', 'status': 'RECRUITING', 'country': 'Austria', 'contacts': [{'name': 'Benesch Martin, MD', 'role': 'CONTACT', 'email': 'martin.benesch@klinikum-graz.at'}], 'facility': 'Medical University Graz', 'geoPoint': {'lat': 47.06733, 'lon': 15.44197}}, {'city': 'Innsbruck', 'status': 'RECRUITING', 'country': 'Austria', 'contacts': [{'name': 'Roman Crazzolara, DR', 'role': 'CONTACT', 'email': 'roman.crazzolara@i-med.ac.at'}], 'facility': 'Landeskrankenhaus-Universitätsklinikum Innsbruck', 'geoPoint': {'lat': 47.26266, 'lon': 11.39454}}, {'city': 'Linz', 'status': 'RECRUITING', 'country': 'Austria', 'contacts': [{'name': 'Barbara Winkler, DR', 'role': 'CONTACT', 'email': 'barbara.aistleitner@keplerklinikum.at'}], 'facility': 'Kepler Universitatsklinikum Linz', 'geoPoint': {'lat': 48.30639, 'lon': 14.28611}}, {'city': 'Salzburg', 'status': 'RECRUITING', 'country': 'Austria', 'contacts': [{'name': 'Neil Jones', 'role': 'CONTACT', 'email': 'n.jones@salk.at'}], 'facility': 'Universitastsklinikum Salzburg', 'geoPoint': {'lat': 47.79941, 'lon': 13.04399}}, {'zip': 'A-1090', 'city': 'Vienna', 'status': 'RECRUITING', 'country': 'Austria', 'contacts': [{'name': 'Ruth Ladenstein, Pr', 'role': 'CONTACT', 'email': 'ruth.ladenstein@ccri.at'}, {'name': 'Carina Rajner', 'role': 'CONTACT', 'email': 'carina.rajner@ccri.at'}, {'name': 'Heidrun Boztug, Dr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "St Anna'S Children Hospital", 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'zip': '1020', 'city': 'Brussels', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Safiato Diallo, MD', 'role': 'CONTACT', 'email': 'safiatou.diallo@huderf.be', 'phone': '0032 2 477 26 78'}], 'facility': 'Hôpital Universitaire des Enfants Reine Fabiola (ULB)', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '1200', 'city': 'Brussels', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Benedicte Brichard, MD', 'role': 'CONTACT', 'email': 'benedicte.brichard@saintluc.uclouvain.be', 'phone': '0032 2 764 23 50'}], 'facility': 'Cliniques Universitaires Saint-Luc (UCL)', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '9000', 'city': 'Ghent', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Wilde, MD', 'role': 'CONTACT', 'email': 'bram.dewilde@uzgent.be', 'phone': '0032 9 332 48 12'}], 'facility': 'University Hospital Gent', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'zip': '3000', 'city': 'Leuven', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Marleen Renard, MD', 'role': 'CONTACT', 'email': 'marleen.renard@uzleuven.be', 'phone': '0032 16 34 39 72'}], 'facility': 'University Hospitals Leuven', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': '4000', 'city': 'Liège', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Sophie Gatineau, MD', 'role': 'CONTACT', 'email': 'sophie.gatineau@chrcitadelle.be', 'phone': '0032 4 321 55 18'}], 'facility': 'CHR Citadelle', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'zip': '15006', 'city': 'Prague', 'state': 'Prague', 'status': 'RECRUITING', 'country': 'Czechia', 'contacts': [{'name': 'Josef Malis, MD', 'role': 'CONTACT', 'email': 'josef.malis@fnmotol.cz', 'phone': '+420 224 436 401'}], 'facility': 'University Hospital Motol', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '662 63', 'city': 'Brno', 'status': 'NOT_YET_RECRUITING', 'country': 'Czechia', 'contacts': [{'name': 'Pavel Pavel, MD', 'role': 'CONTACT', 'email': 'Mazanek.Pavel@fnbrno.cz', 'phone': '+420 532 234 449'}], 'facility': 'Klinika dětské onkologie FN Brno', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'zip': 'DK-8200', 'city': 'Aarhus', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'karin Bækgaard Nissen', 'role': 'CONTACT', 'email': 'karins@rm.dk'}], 'facility': 'Aarhus University Hospital', 'geoPoint': {'lat': 56.15674, 'lon': 10.21076}}, {'zip': 'DK-2100', 'city': 'Copenhagen', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'jesper Sune Brok,, PhD', 'role': 'CONTACT', 'email': 'jesper.sune.brok@regionh.dk', 'phone': '0045 35458270'}], 'facility': 'Department of Paediatrics and Adolescent Medicine, Rigshospitalet', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}, {'zip': 'DK-5000', 'city': 'Odense', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'Mathias Rathe, PhD', 'role': 'CONTACT', 'email': 'mathias.rathe@rsyd.dk', 'phone': '0045 30296665'}], 'facility': "The Hans Christian Andersen Children's Hospital, University of Southern Denmark", 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}}, {'zip': '00029', 'city': 'Helsinki', 'status': 'NOT_YET_RECRUITING', 'country': 'Finland', 'contacts': [{'name': 'Minna Koskenvuo, MD', 'role': 'CONTACT', 'email': 'minna.koskenvuo@hus.fi', 'phone': '+358 50 427 0424'}], 'facility': "New Children's Hospital, Helsinki University Hospital, Helsinki and Uusimaa Hospital District", 'geoPoint': {'lat': 60.16952, 'lon': 24.93545}}, {'city': 'Kuopio', 'status': 'NOT_YET_RECRUITING', 'country': 'Finland', 'contacts': [{'name': 'Kaisa Vepsäläinen, MD', 'role': 'CONTACT', 'email': 'kaisa.vepsalainen@kuh.fi', 'phone': '+358 44 717 4964'}], 'facility': 'Kuopio University Hospital', 'geoPoint': {'lat': 62.89238, 'lon': 27.67703}}, {'city': 'Oulu', 'status': 'NOT_YET_RECRUITING', 'country': 'Finland', 'contacts': [{'name': 'Hanna Juntti, MD', 'role': 'CONTACT', 'email': 'hanna.juntti@pohde.fi', 'phone': '+358 50 579 4440'}], 'facility': 'Oulu University Hospital', 'geoPoint': {'lat': 65.01236, 'lon': 25.46816}}, {'city': 'Tampere', 'status': 'NOT_YET_RECRUITING', 'country': 'Finland', 'contacts': [{'name': 'Sauli Palmu, MD', 'role': 'CONTACT', 'email': 'sauli.palmu@tuni.fi', 'phone': '+358 50 353 9956'}], 'facility': 'Tampere University Hospital', 'geoPoint': {'lat': 61.49911, 'lon': 23.78712}}, {'city': 'Turku', 'status': 'NOT_YET_RECRUITING', 'country': 'Finland', 'contacts': [{'name': 'Marika Grönroos, MD', 'role': 'CONTACT', 'email': 'marika.gronroos@varha.fi', 'phone': '+358 2 3130646'}], 'facility': 'Turku University Hospital', 'geoPoint': {'lat': 60.45148, 'lon': 22.26869}}, {'zip': '94800', 'city': 'Villejuif', 'state': 'Val De Marne', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Claudia Pasqualini, MD PhD', 'role': 'CONTACT', 'email': 'claudia.pasqualini@gustaveroussy.fr', 'phone': '+33 (0)1 42 11 42 11'}, {'name': 'Attalah Habiba, PhD', 'role': 'CONTACT', 'email': 'habiba.attalah@gustaveroussy.fr', 'phone': '+33 (0)1 42 11 64 46'}], 'facility': 'Gustave Roussy', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}, {'zip': '80054', 'city': 'Amiens', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Leslie Andry, MD', 'role': 'CONTACT', 'email': 'andry.leslie@chu-amiens.fr'}], 'facility': "CHU d'AMIENS", 'geoPoint': {'lat': 49.9, 'lon': 2.3}}, {'city': 'Angers', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Stéphanie Proust, MD', 'role': 'CONTACT', 'email': 'stproust@chu-angers.fr'}], 'facility': 'CHU angers', 'geoPoint': {'lat': 47.47156, 'lon': -0.55202}}, {'city': 'Besançon', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Veronique LAITHIER, MD', 'role': 'CONTACT', 'email': 'vlaithier@chu-besancon.fr'}], 'facility': "CHU-Pôle Médico-Chirurgical de l'Enfant et l'Adolescant", 'geoPoint': {'lat': 47.24878, 'lon': 6.01815}}, {'zip': '33600', 'city': 'Bordeaux', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Ayemeri Huchet, MD', 'role': 'CONTACT', 'email': 'ayemeri.huchet@chu-bordeaux.fr'}], 'facility': 'CHU Bordeaux', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'city': 'Bordeaux', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Julie Tandonnet, MD', 'role': 'CONTACT', 'email': 'julie.tandonnet@chu-bordeaux.fr'}], 'facility': 'Groupe Hospitalier Pellegrin - Chu - Bordeaux', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'zip': '29609', 'city': 'Brest', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Liana Carausu, MD', 'role': 'CONTACT', 'email': 'liana.carausu@chu-brest.fr'}], 'facility': 'CHU Brest', 'geoPoint': {'lat': 48.39029, 'lon': -4.48628}}, {'city': 'Brest', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Liana CARAUSU, MD', 'role': 'CONTACT', 'email': 'liana.carausu@chu-brest.fr'}], 'facility': 'CHU Brest - Hôpital du Morvan', 'geoPoint': {'lat': 48.39029, 'lon': -4.48628}}, {'city': 'Caen', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'France', 'facility': 'Centre François Baclesse', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'city': 'Caen', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Damien Bodet, MD', 'role': 'CONTACT', 'email': 'bodet-d@chu-caen.fr'}], 'facility': 'CHU de Caen', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'city': 'Clermont-Ferrand', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'justyna KANOLD, MD', 'role': 'CONTACT', 'email': 'jkanold@chu-clermontferrand.fr'}], 'facility': 'CHU Estaing', 'geoPoint': {'lat': 45.77969, 'lon': 3.08682}}, {'city': 'Dijon', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'France', 'facility': 'Centre Georges-François Leclerc', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'city': 'Dijon', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'claire BRIANDET, MD', 'role': 'CONTACT', 'email': 'claire.briandet@chu-dijon.fr'}], 'facility': "Hopital d'enfants Marechal de lattre", 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'city': 'Grenoble', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Dominique Plantaz, MD', 'role': 'CONTACT', 'email': 'dplantaz@chu-grenoble.fr'}], 'facility': 'Hôpital Couple-Enfant CHU de Grenoble', 'geoPoint': {'lat': 45.17869, 'lon': 5.71479}}, {'city': 'La Réunion', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Yves REGUERRE, MD', 'role': 'CONTACT', 'email': 'yves.reguerre@chu-reunion.fr'}], 'facility': 'Chu de La Reunion - St Denis', 'geoPoint': {'lat': 44.29707, 'lon': 0.11776}}, {'city': 'Lille', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Anne-Sophie DEFACHELLES', 'role': 'CONTACT', 'email': 'AS-Defachelles@o-lambret.fr'}], 'facility': 'centre Oscar lambert', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'city': 'Limoges', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'christophe PIGUET, MD', 'role': 'CONTACT', 'email': 'christophe.piguet@chu-limoges.fr'}], 'facility': "Hôpital de la Mère et de l'Enfant - CHU Limoges", 'geoPoint': {'lat': 45.83362, 'lon': 1.24759}}, {'city': 'Lyon', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Benoit Dumond, MD', 'role': 'CONTACT', 'email': 'Benoit.DUMONT@ihope.fr'}], 'facility': 'Centre Léon Berard', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'city': 'Marseille', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'carole coze, MD', 'role': 'CONTACT', 'email': 'carole.coze@ap-hm.fr'}], 'facility': 'hopital la Timone', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'city': 'Nancy', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Ludovic Mansuy, MD', 'role': 'CONTACT', 'email': 'lu.mansuy@chru-nancy.fr'}], 'facility': 'CHRU Nancy-Hôpital Brabois Enfant', 'geoPoint': {'lat': 48.68439, 'lon': 6.18496}}, {'city': 'Nancy', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'France', 'facility': 'Institut de cancérologie de Loraine', 'geoPoint': {'lat': 48.68439, 'lon': 6.18496}}, {'city': 'Nice', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'France', 'facility': 'Centre Antoine Lacassagne', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'city': 'Nice', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Joy Benadiba', 'role': 'CONTACT', 'email': 'benadiba.j@chu-nice.fr'}], 'facility': "CHU Nice-Hôpital d'Archet", 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Arnaud Petit, MD', 'role': 'CONTACT', 'email': 'arnaud.petit@aphp.fr'}], 'facility': 'Hôpital Armand Trousseau', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Gudrun SCHLEIERMACHER, MD ;PhD', 'role': 'CONTACT', 'email': 'gudrun.schleiermacher@curie.fr'}], 'facility': 'institut Curie', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Poitiers', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Frederic Millot, MD', 'role': 'CONTACT', 'email': 'Frederic.MILLOT@chu-poitiers.fr'}], 'facility': 'CHU Poitiers', 'geoPoint': {'lat': 46.58261, 'lon': 0.34348}}, {'city': 'Reims', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Claire PLUCHART, MD', 'role': 'CONTACT', 'email': 'cpluchart@chu-reims.fr'}], 'facility': 'Hôpital Américain -CHU Reims', 'geoPoint': {'lat': 49.26526, 'lon': 4.02853}}, {'city': 'Rennes', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'France', 'facility': 'Centre Eugène Marquis', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'city': 'Rennes', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'sophie taque, MD', 'role': 'CONTACT', 'email': 'sophie.taque@chu-rennes.fr'}], 'facility': 'CHU Rennes', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'city': 'Rouen', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'cecile DUMESNIL DE MAURICOURT, MD', 'role': 'CONTACT', 'email': 'Cecile.Dumesnil@chu-rouen.fr'}], 'facility': 'Hôpital des Enfants - CHU Rouen', 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'city': 'Saint-Etienne', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'sandrine THOUVENIN-DOULET, MD', 'role': 'CONTACT', 'email': 'sandrine.thouvenin@chu-st-etienne.fr'}], 'facility': 'CHU Saint Etienne', 'geoPoint': {'lat': 45.43389, 'lon': 4.39}}, {'city': 'Saint-Herblain', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'France', 'facility': "Institut de cancérologie de l'Ouest - Sité René Gauducheau", 'geoPoint': {'lat': 47.21154, 'lon': -1.651}}, {'city': 'Strasbourg', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'catherine PAILLARD, MD', 'role': 'CONTACT', 'email': 'catherine.paillard@chru-strasbourg.fr'}], 'facility': 'CHU Haute Pierre', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'city': 'Strasbourg', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'France', 'facility': 'Institut de Cancérologie Strasbourg', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'city': 'Toulouse', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Marion Gambart, MD', 'role': 'CONTACT', 'email': 'gambart.m@chu-toulouse.fr'}], 'facility': 'Hopital des enfants-CHU Toulouse', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'city': 'Toulouse', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'France', 'facility': 'IUCT Oncopole', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'city': 'Tours', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Pascal Blouin, MD', 'role': 'CONTACT', 'email': 'p.blouin@chu-tours.fr'}], 'facility': 'CHU Tours Hôpital Clocheville', 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}, {'zip': '13353', 'city': 'Berlin', 'status': 'RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Angelika eggert, Pr', 'role': 'CONTACT', 'email': 'angelika.eggert@charite.de', 'phone': '49 30 450 566 132'}], 'facility': 'charite universitatsmedizin Berlin', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '50937', 'city': 'Cologne', 'status': 'NOT_YET_RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Thorsten Simon, MD', 'role': 'CONTACT', 'email': 'thorsten.simon@uk-koeln.de', 'phone': '+49 221 478 6853'}], 'facility': 'Uniklinik Köln, Klinik und Poliklinik für Kinder und Jugendmedizin', 'geoPoint': {'lat': 50.93333, 'lon': 6.95}}, {'zip': '11527', 'city': 'Athens', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'Vassilios papadakis, MD', 'role': 'CONTACT', 'email': 'vpapadak@otenet.gr', 'phone': '0030 210-7452020, 2018'}], 'facility': 'Children\'s General Hospital "I AGHIA SOFIA"', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '11527', 'city': 'Athens', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'Margarita BAKA, MD', 'role': 'CONTACT', 'email': 'margbaka@hotmail.com', 'phone': '0030 2107452219'}], 'facility': 'Children\'s General Hospital "P. & A. KYRIAKOU"', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '15123', 'city': 'Athens', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'DANA ELENI, MD', 'role': 'CONTACT', 'email': 'danaeleni@hotmail.gr', 'phone': '0030 210 6869631'}], 'facility': '"MITERA" Private, General, Obstetrics - Gynaecology, Paediatric Clinic S.A.', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'city': 'Athens', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'ANTONIOS KATTAMIS, MD', 'role': 'CONTACT', 'email': 'ankatt@med.uoa.gr', 'phone': '0030 2107452121'}], 'facility': 'Children\'s General Hospital "AGHIA SOFIA"', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '71500', 'city': 'Heraklion', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'NIKOLAOS KATZILAKIS, MD', 'role': 'CONTACT', 'email': 'katzilaher@yahoo.gr', 'phone': '0030 2810 392630'}], 'facility': 'University General Hospital of Heraklion (UnGHH)', 'geoPoint': {'lat': 35.32787, 'lon': 25.14341}}, {'zip': '54621', 'city': 'Thessaloniki', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'EMMANOUEL HATZIPANTELIS, MD', 'role': 'CONTACT', 'email': 'hatzip@auth.gr', 'phone': '0030 2310994810'}], 'facility': 'University General Hospital of Thessaloniki "AHEPA"', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': '54642', 'city': 'Thessaloniki', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'EVGENIA PAPAKONSTANTINOU, MD', 'role': 'CONTACT', 'email': 'eugepapa@yahoo.gr', 'phone': '0030 2313312430'}], 'facility': 'General Hospital of Thessaloniki "IPPOKRATIO"', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'city': 'Haifa', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'shifra Ash, Pr', 'role': 'CONTACT', 'email': 'S_ash@rmc.gov.il'}], 'facility': 'RAMBAM Medical Center', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '70124', 'city': 'Bari', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Nicola santoro, MD', 'role': 'CONTACT', 'email': 'nico.santoro1956@libero.it', 'phone': '0805593363'}], 'facility': 'A.O.U Policlinico di Bari', 'geoPoint': {'lat': 41.12066, 'lon': 16.86982}}, {'zip': '3995041', 'city': 'Brescia', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Fulvio porta', 'role': 'CONTACT', 'email': 'fulvio.porta@asst-spedalicivili.it', 'phone': '0303995711'}], 'facility': 'Spedali civili Ospedale Dei Bambini Oncoematologia pediatrica e TMO', 'geoPoint': {'lat': 45.53558, 'lon': 10.21472}}, {'zip': '95123', 'city': 'Catania', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Andrea di cataldo, MD', 'role': 'CONTACT', 'email': 'adicata@unict.it', 'phone': '095/3782683'}], 'facility': 'policlinico rodolico San marco', 'geoPoint': {'lat': 37.49223, 'lon': 15.07041}}, {'zip': '50139', 'city': 'Florence', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'annalisa Tondo, MD', 'role': 'CONTACT', 'email': 'annalisa.tondo@meyer.it', 'phone': '055/56622739'}], 'facility': 'Azienda ospedaliero universtaria Anna Meyer', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'zip': '16147', 'city': 'Genova', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'alberto garaventa, MD', 'role': 'CONTACT', 'email': 'albertogaraventa@gaslini.org', 'phone': '010/563662410'}], 'facility': 'instituto Giannina Gaslini genova', 'geoPoint': {'lat': 45.21604, 'lon': 11.87211}}, {'zip': '16147', 'city': 'Genova', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Garaventa Alberto, MD', 'role': 'CONTACT', 'email': 'albertogaraventa@gaslini.org', 'phone': '01056362410'}], 'facility': 'IRCCS "Istituto Giannina Gaslini"', 'geoPoint': {'lat': 45.21604, 'lon': 11.87211}}, {'zip': '41100', 'city': 'Modena', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'ssa Monica Cellini, MD', 'role': 'CONTACT', 'email': 'cellini.monica@policlinico.mo.it', 'phone': '059/4224485-2837'}], 'facility': 'Azienda Policlinico di Modena', 'geoPoint': {'lat': 44.64783, 'lon': 10.92539}}, {'zip': '43126', 'city': 'Parma', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'patrizia Bertolini, MD', 'role': 'CONTACT', 'email': 'pbertolini@ao.pr.it', 'phone': '0521/702831'}], 'facility': 'Azienda ospedaliero universitaria di Parma', 'geoPoint': {'lat': 44.79935, 'lon': 10.32618}}, {'zip': '27100', 'city': 'Pavia', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'frederico Bonetti, MD', 'role': 'CONTACT', 'email': 'f.bonetti@smatteo.pv.it', 'phone': '0382/502607'}], 'facility': 'Policlino San matteo di Pavia', 'geoPoint': {'lat': 45.19205, 'lon': 9.15917}}, {'zip': '47900', 'city': 'Rimini', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Roberta Pericoli, MD', 'role': 'CONTACT', 'email': 'roberta.pericoli@auslromagna.it', 'phone': '0541/705034'}], 'facility': 'U.O Pediatria, SS Oncoematologia pediatrica', 'geoPoint': {'lat': 44.05755, 'lon': 12.56528}}, {'zip': '34137', 'city': 'Trieste', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'marco Rabusin', 'role': 'CONTACT', 'email': 'marco.rabusin@burlo.triete.it', 'phone': '0403785563'}], 'facility': 'IRCCS Burlo Garoflo oncoematologia', 'geoPoint': {'lat': 45.64953, 'lon': 13.77678}}, {'zip': '37126', 'city': 'Verona', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'simone cesaro, MD', 'role': 'CONTACT', 'email': 'simone.cesaro@ospedaleuniverona.it', 'phone': '0458127874'}], 'facility': 'U.O.C oncoematologia pediatrica ospedale Donna Bambino', 'geoPoint': {'lat': 45.43854, 'lon': 10.9938}}, {'zip': '08406', 'city': 'Vilnius', 'status': 'NOT_YET_RECRUITING', 'country': 'Lithuania', 'contacts': [{'name': 'Jelena Rascon, Pr', 'role': 'CONTACT', 'email': 'jelena.rascon@santa.lt', 'phone': '+370 5 232 8703'}], 'facility': 'Vilnius University Hospital Santaros Klinikos', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': '08660', 'city': 'Vilnius', 'status': 'NOT_YET_RECRUITING', 'country': 'Lithuania', 'contacts': [{'name': 'Daiva Sendiuliene, MD', 'role': 'CONTACT', 'email': 'daiva.sendiuliene@nvi.lt', 'phone': '+370 5 274 6468'}], 'facility': 'National Cancer Institute', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': '9700', 'city': 'Groningen', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'Netherlands', 'facility': 'Universitair Medisch Centrum Groningen', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}, {'zip': '3584CS', 'city': 'Utrecht', 'status': 'RECRUITING', 'country': 'Netherlands', 'contacts': [{'name': 'Lieve TyTGAT, MD', 'role': 'CONTACT', 'email': 'G.A.M.Tytgat@prinsesmaximacentrum.nl', 'phone': '+31 06-55234711'}, {'name': 'JAAP MUR', 'role': 'CONTACT', 'email': 'J.Mur@prinsesmaximacentrum.nl', 'phone': '+31 06 5000 66 46'}], 'facility': 'Princess Maxima center', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}, {'city': 'Haukeland', 'status': 'RECRUITING', 'country': 'Norway', 'contacts': [{'name': 'Maria Winther Gunnes, MD', 'role': 'CONTACT', 'email': 'maria.gunnes@helse-bergen.no'}], 'facility': 'Haukeland University Hospital', 'geoPoint': {'lat': 60.36333, 'lon': 5.45139}}, {'zip': '0424', 'city': 'Oslo', 'status': 'RECRUITING', 'country': 'Norway', 'contacts': [{'name': 'Maria Winther Gunnes', 'role': 'CONTACT', 'email': 'mawgun@ous-hf.no'}], 'facility': 'Oslo University Hospital', 'geoPoint': {'lat': 59.91273, 'lon': 10.74609}}, {'city': 'Tromsø', 'status': 'NOT_YET_RECRUITING', 'country': 'Norway', 'contacts': [{'name': 'Trond Flaegstad, MD', 'role': 'CONTACT', 'email': 'trond.flaegstad@unn.no'}], 'facility': 'University Hospital Northern Norway, Tromsoe', 'geoPoint': {'lat': 69.6489, 'lon': 18.95508}}, {'city': 'Trondheim', 'status': 'NOT_YET_RECRUITING', 'country': 'Norway', 'contacts': [{'name': 'MOE Erling, MD', 'role': 'CONTACT', 'email': 'erling.moe@stolav.no'}], 'facility': 'St Olavs Hospital,', 'geoPoint': {'lat': 63.43049, 'lon': 10.39506}}, {'zip': '974 09', 'city': 'Banská Bystrica', 'status': 'NOT_YET_RECRUITING', 'country': 'Slovakia', 'contacts': [{'name': 'pavel Bician, MD', 'role': 'CONTACT', 'email': 'pavel.bician@dfnbb.sk', 'phone': '421 907 808 363'}], 'facility': "Children's University Hospital Banská Bystrica", 'geoPoint': {'lat': 48.73947, 'lon': 19.14932}}, {'zip': '833 40', 'city': 'Bratislava', 'status': 'NOT_YET_RECRUITING', 'country': 'Slovakia', 'contacts': [{'name': 'Achbergerová Monika, MD', 'role': 'CONTACT', 'email': 'monika.achbergerova@fmed.uniba.sk'}], 'facility': "NÚDCH- National Institute of Children's Diseases,", 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'zip': '040 11', 'city': 'Košice', 'status': 'NOT_YET_RECRUITING', 'country': 'Slovakia', 'contacts': [{'name': 'Halušková Viktória, MD', 'role': 'CONTACT', 'email': 'viktoria.haluskova@dfnkosice.sk', 'phone': '055 235 3227'}], 'facility': "Children's University Hospital Košice", 'geoPoint': {'lat': 48.71441, 'lon': 21.25802}}, {'zip': '1000', 'city': 'Ljubljana', 'status': 'RECRUITING', 'country': 'Slovenia', 'contacts': [{'name': 'Cesen maja, MD', 'role': 'CONTACT', 'email': 'maja.cesenmazic@kclj.si', 'phone': ': 00 386 41 365 384'}], 'facility': "University medical center Ljubljana, University Children's Hospital Ljubljana, Slovenia", 'geoPoint': {'lat': 46.05108, 'lon': 14.50513}}, {'zip': '07010', 'city': 'Balea', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'samuel Navarro Noguera, MD', 'role': 'CONTACT', 'email': 'samuel.navarro@ssib.es', 'phone': '+34871205000'}], 'facility': 'Hospital Universitario Son Espases', 'geoPoint': {'lat': 42.2531, 'lon': -8.79484}}, {'zip': '08035', 'city': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Lucas Moreno Martin, MD', 'role': 'CONTACT', 'email': 'lucas.moreno@vallhebron.cat', 'phone': '+34934893093'}], 'facility': 'Hospital Universitario Vall D´Hebron', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '48903', 'city': 'Cruces', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Ricardo Lopez Almaraz, MD', 'role': 'CONTACT', 'email': 'RICARDO.LOPEZALMARAZ@osakidetza.eus', 'phone': '+34946006289'}], 'facility': 'Hospital Universitario Cruces', 'geoPoint': {'lat': 42.79471, 'lon': -8.17208}}, {'zip': '30120', 'city': 'El Palmar', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Maria Del Mar Bermudez, MD', 'role': 'CONTACT', 'email': 'mariam.bermudez2@carm.es', 'phone': '+34968929461'}], 'facility': 'Hospital Clínico Universitario Virgen de la Arrixaca', 'geoPoint': {'lat': 39.31305, 'lon': -0.3174}}, {'zip': '28009', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Alba Rubio San Simon, MD', 'role': 'CONTACT', 'email': 'alba.rubio@salud.madrid.org', 'phone': '+34915035900'}], 'facility': 'Hospital Universitario Infantil Niño Jesús', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28046', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Pedro rubio Aparicio, MD', 'role': 'CONTACT', 'email': 'pedro.rubio@salud.madrid.org', 'phone': '+34912071116'}], 'facility': 'Hospital Universitario La Paz', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '29010', 'city': 'Málaga', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Laura Garcia Hidalgo, MD', 'role': 'CONTACT', 'email': 'laura.garcia.hidalgo.sspa@juntadeandalucia.es', 'phone': '+34662244641'}], 'facility': 'Hospital Regional Universitario de Málaga', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'zip': '20014', 'city': 'San Sebastián', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Miriam Abos Garcia, MD', 'role': 'CONTACT', 'email': 'miriam.garciaabos@osakidetza.eus', 'phone': '+34943007176'}], 'facility': 'Hospital Universitario Donostia', 'geoPoint': {'lat': 43.56667, 'lon': -5.9}}, {'zip': '15706', 'city': 'Santiago de Compostela', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Manuel Fernández Sanmartín, MD', 'role': 'CONTACT', 'email': 'manuel.fernandez.sanmartin@sergas.es', 'phone': '+34981951120'}], 'facility': 'Hospital Clínico Universitario de Santiago', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'zip': '41013', 'city': 'Seville', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'catalina Marquez Vega, MD', 'role': 'CONTACT', 'email': 'catalina.marquez.sspa@juntadeandalucia.es', 'phone': '+34955012921'}], 'facility': 'Hospital Universitario Virgen del Rocío', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'city': 'Valencia', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Adela canete, MD', 'role': 'CONTACT', 'email': 'canyete_ade@gva.es', 'phone': '+34961244900'}], 'facility': 'Hospital Universitario Politécnico de La FE', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'city': 'Gothenburg', 'status': 'NOT_YET_RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Torben Ek, MD', 'role': 'CONTACT', 'email': 'Torben.ek@vgregion.se'}], 'facility': 'Sahlgrenska University Hospital', 'geoPoint': {'lat': 57.70716, 'lon': 11.96679}}, {'city': 'Linköping', 'status': 'NOT_YET_RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Lisa Törnudd, MD', 'role': 'CONTACT'}], 'facility': 'Linköping University Hospital', 'geoPoint': {'lat': 58.41086, 'lon': 15.62157}}, {'city': 'Lund', 'status': 'NOT_YET_RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Ingrid Øra Ingrid Øra, MD', 'role': 'CONTACT', 'email': 'Ingrid.ora@med.lu.se'}], 'facility': 'Skåne University Hospital', 'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}, {'city': 'Stockholm', 'status': 'NOT_YET_RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Kleopatra Georgantzi, MD', 'role': 'CONTACT', 'email': 'kleopatra.georgantzi@regionstockholm.se'}], 'facility': 'Karolinska University Hospital, Stockholm', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}, {'city': 'Umeå', 'status': 'NOT_YET_RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Caroline Björklund, MD', 'role': 'CONTACT', 'email': 'caroline.bjorklund@regionvasterbotten.se'}], 'facility': 'Norrland University Hospital', 'geoPoint': {'lat': 63.82842, 'lon': 20.25972}}, {'city': 'Uppsala', 'status': 'NOT_YET_RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Träger Träger, MD', 'role': 'CONTACT', 'email': 'catarina.trager@akademiska.se'}], 'facility': 'Uppsala University Hospital', 'geoPoint': {'lat': 59.85882, 'lon': 17.63889}}, {'zip': 'CH-5001', 'city': 'Aarau', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Andreas Klein-Franke, MD', 'role': 'CONTACT', 'email': 'Andreas.Klein-Franke@ksa.ch', 'phone': '41 62 838 92 45'}], 'facility': 'Kantonsspital Aarau AG Klinik für Kinder und Jugendliche', 'geoPoint': {'lat': 47.39254, 'lon': 8.04422}}, {'zip': 'CH-4031', 'city': 'Basel', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Nicolas von der Weid, Pr', 'role': 'CONTACT', 'email': 'nicolas.vonderweid@ukbb.ch', 'phone': '41 61 704 17 62'}], 'facility': 'Universitäts-Kinderspital beider Basel (UKBB)', 'geoPoint': {'lat': 47.55839, 'lon': 7.57327}}, {'zip': 'CH-6500', 'city': 'Bellinzona', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Pierluigi Brazzola, MD', 'role': 'CONTACT', 'email': 'Pierluigi.Brazzola@eoc.ch', 'phone': '41 91 811 89 76'}], 'facility': 'Ospedale San Giovanni Pediatria, Emato-oncologia pediatrica', 'geoPoint': {'lat': 46.19278, 'lon': 9.01703}}, {'zip': 'CH-3010', 'city': 'Bern', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Jochen Rößler, MD', 'role': 'CONTACT', 'email': 'jochen.roessler@insel.ch', 'phone': '41 31 632 94 95'}], 'facility': 'Inselspital, Universitätsklinik für Kinderheilkunde', 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}, {'zip': 'CH-1205', 'city': 'Geneva', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Fabienne Gumy Pause, MD', 'role': 'CONTACT', 'email': 'fabienne.gumypause@hcuge.ch', 'phone': '41 79 55 32 594'}], 'facility': "HUG Hôpitaux Universitaires de Genève Unité d'Hémato-Oncologie Pédiatrique", 'geoPoint': {'lat': 46.20222, 'lon': 6.14569}}, {'zip': 'CH-1011', 'city': 'Lausanne', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Maja Beck Popovic, Pr', 'role': 'CONTACT', 'email': 'maja.beck-popovic@chuv.ch', 'phone': '41 21 314 35 67'}], 'facility': 'CHUV - Centre Hospitalier Universitaire Vaudois', 'geoPoint': {'lat': 46.516, 'lon': 6.63282}}, {'zip': 'CH-6000', 'city': 'Lucerne', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Freimut H. Schilling, MD', 'role': 'CONTACT', 'email': 'freimut.schilling@luks.ch', 'phone': '+41 41 205 32 10'}], 'facility': 'Luzerner Kantonsspital, Kinderspital pädiatrische Hämatologie/Onkologie', 'geoPoint': {'lat': 47.05048, 'lon': 8.30635}}, {'zip': 'CH-9006', 'city': 'Sankt Gallen', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Cornelia Vetter, MD', 'role': 'CONTACT', 'email': 'cornelia.vetter@kispisg.ch', 'phone': '+41 71 243 13 48'}], 'facility': 'Ostschweizer Kinderspital Hämatologie/Onkologie Claudiusstrasse 6', 'geoPoint': {'lat': 47.42391, 'lon': 9.37477}}, {'zip': 'CH-8032', 'city': 'Zurich', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Sabina Kroiss Benninger, MD', 'role': 'CONTACT', 'email': 'sabine.kroiss@kispi.uzh.ch', 'phone': '41 44 266 70 57'}], 'facility': 'Division of Pediatric Oncology Universitäts-Kinderspital Zürich', 'geoPoint': {'lat': 47.36667, 'lon': 8.55}}, {'city': 'Aberdeen', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Fiona HERD, MD', 'role': 'CONTACT', 'email': 'fiona.herd2@nhs.scot'}], 'facility': "Royal Aberdeen Children's Hospital", 'geoPoint': {'lat': 57.14369, 'lon': -2.09814}}, {'city': 'Belfast', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Robert JOHNSTON, MD', 'role': 'CONTACT', 'email': 'Robert.johnston@belfasttrust.hscni.net'}], 'facility': 'Royal Belfast Hospital for Sick Children', 'geoPoint': {'lat': 54.59682, 'lon': -5.92541}}, {'zip': 'B46NH', 'city': 'Birmingham', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'David Hobin, MD', 'role': 'CONTACT', 'email': 'davidhobin@nhs.net', 'phone': '01213338258'}], 'facility': "Birmingham children's Hospital", 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'B46NH', 'city': 'Birmingham', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United Kingdom', 'facility': 'University Hospitals Birmingham Queen Elisabeth Hospital(UHB)', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'BS1 3NU', 'city': 'Bristol', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Antony NG, MD', 'role': 'CONTACT', 'email': 'antony.ng@uhbristol.nhs.uk'}], 'facility': 'University Hospitals Bristol and Weston NHS Foundation Trust', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'city': 'Cambridge', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Matthew MURRAY, MD', 'role': 'CONTACT', 'email': 'matthew.murray1@nhs.net'}], 'facility': 'Addenbrookes Hospital, Cambridge', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'city': 'Cardiff', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Cathy MORLEY-JACOB, MD', 'role': 'CONTACT', 'email': 'Charlotte.Chambers@wales.nhs.uk'}], 'facility': "Noah's Ark Children's Hospital for Wales - Cardiff", 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'city': 'Edinburgh', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Lesley SIMPSON, MD', 'role': 'CONTACT', 'email': 'Lesley.a.simpson@nhslothian.scot.nhs.uk'}], 'facility': 'Royal Hospital for Sick Children - Edinburgh', 'geoPoint': {'lat': 55.95206, 'lon': -3.19648}}, {'zip': 'G34', 'city': 'Glasgow', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Dermot Murphy, MD', 'role': 'CONTACT', 'email': 'Dermot.Murphy@ggc.scot.nhs.uk'}], 'facility': 'Royal Hospital for Children Glasgow', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'city': 'Leeds', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Martin ELLIOTT, MD', 'role': 'CONTACT', 'email': 'martin.elliott1@nhs.net'}], 'facility': 'Leeds General Infirmary', 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'city': 'Liverpool', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Lisa HOWELL, MD', 'role': 'CONTACT', 'email': 'Lisa.Howell@alderhey.nhs.uk'}], 'facility': "Alder Hey Children's Hospital - Liverpool", 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Giuseppe BARONE, MD', 'role': 'CONTACT', 'email': 'giuseppe.barone@gosh.nhs.uk'}], 'facility': 'Great Ormond Street Hospital - London', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'Manchester', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': "Royal Manchester Children's Hospital", 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'city': 'Newcastle', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Deborah Tweddle, MD', 'role': 'CONTACT', 'email': 'deborah.tweddle@newcastle.ac.uk', 'phone': '0912082230'}], 'facility': 'Royal Victoria Infirmary, Newcastle', 'geoPoint': {'lat': 54.21804, 'lon': -5.88979}}, {'city': 'Nottingham', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'MADNI MADNI, MD', 'role': 'CONTACT', 'email': 'majid.madni@nuh.nhs.uk'}], 'facility': "Nottingham Children's Hospital", 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}, {'zip': 'S102TH', 'city': 'Sheffield', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Dan Yeomanson, MD', 'role': 'CONTACT', 'email': 'danyeomanson@nhs.net', 'phone': '01142717366'}], 'facility': "Sheffield Children's Hospital", 'geoPoint': {'lat': 53.38297, 'lon': -1.4659}}, {'city': 'Southampton', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Ramya RAMANUJACHAR, MD', 'role': 'CONTACT', 'email': 'ramya.ramanujachar@uhs.nhs.uk'}], 'facility': 'Southampton General Hospital', 'geoPoint': {'lat': 50.90395, 'lon': -1.40428}}, {'zip': 'SM2 5PT', 'city': 'Sutton', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Sucheta vaidya, MD', 'role': 'CONTACT', 'email': 'sucheta.vaidya@icr.ac.uk', 'phone': '02086613635'}], 'facility': 'Royal Marsden Hospital', 'geoPoint': {'lat': 51.35, 'lon': -0.2}}], 'centralContacts': [{'name': 'Claudia Pasqualini, MD PhD', 'role': 'CONTACT', 'email': 'claudia.pasqualini@gustaveroussy.fr', 'phone': '+33 (0)1 42 11 42 11'}, {'name': 'Habiba Attalah, PhD', 'role': 'CONTACT', 'email': 'habiba.attalah@gustaveroussy.fr', 'phone': '+33 (0)1 42 11 64 46'}], 'overallOfficials': [{'name': 'Claudia Pasqualini, MD PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Gustave roussy, Paris, France'}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL', 'ICF', 'CSR'], 'ipdSharing': 'YES'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Gustave Roussy, Cancer Campus, Grand Paris', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}